MDT Stock Recent News

Dividend Kings are the most durable dividend stocks, having increased their payouts annually for at least 50 consecutive years. This resilience is impressive, as they've weathered at least seven recessions in that time.

Medtronic (MDT) concluded the recent trading session at $91.24, signifying a +2.1% move from its prior day's close.

GALWAY, Ireland , Aug. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025, for its first quarter of fiscal year 2026, which ended on Friday, July 25, 2025, A news release containing summary financial information will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com A video webcast to discuss results will begin at 7:00 a.m.

Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Medical device specialist Medtronic (MDT -1.02%) has not been the best of investments over the past five years. The stock has significantly lagged the market over this period, thanks to weak business fundamentals, including slow revenue growth.

Medtronic's decade-long underperformance stems from stagnant revenue growth, declining margins, and inconsistent returns on invested capital, despite a solid dividend history. The Diabetes segment spin-off aims to refocus Medtronic on higher-margin, growth areas, potentially improving financial metrics over time. Dividend growth has slowed significantly, with recent increases barely above 1%, reflecting rising payout ratios and limited earnings growth.

Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at it.

What makes a good dividend stock? The answer depends a bit on who's looking, of course.

GALWAY, Ireland , July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the MiniMed™ 780G system for use by individuals aged 2 years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published clinical data in 2–6-year-olds, pregnant women, and people living with type 2 diabetes was reviewed.

Dividend stocks are one of the most powerful wealth compounders. The S&P 500 (SNPINDEX: ^GSPC) index offers the perfect example.